PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-1.47%
Negative net income growth while RVPH stands at 5.90%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
-1.12%
Negative yoy D&A while RVPH is 0.00%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
11.01%
Deferred tax of 11.01% while RVPH is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
20.13%
SBC growth while RVPH is negative at -56.99%. John Neff would see competitor possibly controlling share issuance more tightly.
171.56%
Well above RVPH's 125.07% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
36.25%
Lower AP growth vs. RVPH's 101.70%, indicating prompt payments. David Dodd would confirm no lost opportunity in interest-free credit if expansions are underfunded.
60.10%
Lower 'other working capital' growth vs. RVPH's 159.63%. David Dodd would see fewer unexpected short-term demands on cash.
20.13%
Lower 'other non-cash' growth vs. RVPH's 81.82%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
23.86%
Operating cash flow growth at 50-75% of RVPH's 38.83%. Martin Whitman would worry about lagging operational liquidity vs. competitor.
-1272.99%
Negative yoy CapEx while RVPH is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1272.99%
We reduce yoy invests while RVPH stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
-196.64%
We cut debt repayment yoy while RVPH is 52.51%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
1193.74%
Lower share issuance yoy vs. RVPH's 4129.39%, implying less dilution. David Dodd would confirm the firm still has enough capital for expansions.
No Data
No Data available this quarter, please select a different quarter.